우울증 치료에서 빠른 효과와 적은 부작용을 가진 새로운 N-Methyl-D-Aspartate(NMDA) 수용체 길항제
- Alternative Title
- Other N-Methyl-D-Aspartate (NMDA) Receptor Antagonists with a Rapid Onset of Action and Less Side Effect in the Treatment of Depression
- Abstract
- Mood disorder is a common psychiatric illness with a high lifetime prevalence in the general population. Many prescribed antidepressants modulate monoamine neurotransmitters including serotonin, norepinephrine and dopamine. There has been greater focus on the major excitatory neurotransmitter in the human brain, glutamate, in the pathophysiology and treatment of major depressive disorder (MDD). Recently, ketamine, an N-methyl-D-aspartate receptor antagonist, has received attention and has been investigated for clinical trials and neurobiological studies. In this article, we will review the clinical evidence for glutamatergic dysfunction in MDD, the progress with ketamine as a rapidly acting antidepressant, and other N-methyl-D-aspartate receptor antagonist for treatment-resistant depression.
- All Author(s)
- B. S. Choi
; H. Y. Lee
- Issued Date
- 2015
- Type
- Article
- Keyword
- Major depressive disorder; Glutamate; NMDA receptor antagonist; Ketamine
- Publisher
- 대한생물정신의학회
The Korean Society of Biological Psychiatry
- ISSN
- 1225-8709
; 2005-7571
- Citation Title
- Korean Journal of Biological Psychiatry
- Citation Volume
- 22
- Citation Number
- 4
- Citation Start Page
- 149
- Citation End Page
- 154
- Language(ISO)
- kor
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/3065
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.